Basic Daonil Information

• INN (International Nonproprietary Name): Glyburide (also known as glibenclamide in several international markets).
• Brand Names Available In United Kingdom: not specified.
• ATC Code: A10BB09.
• Forms & Dosages: Tablets 1.25 mg, 2.5 mg and 5 mg; no creams or parenteral forms marketed.
• Manufacturers In United Kingdom: not specified.
• Registration Status In United Kingdom: Registered as glyburide/glibenclamide in many markets; generally prescription-only.
• OTC / Rx Classification: Prescription only (Rx) in nearly all global markets; not sold over the counter.

Latest Research Highlights (Uk And Eu 2022–2025)

Worried about what the latest UK and EU evidence says about sulfonylureas like glyburide?

Recent regional literature continues to treat second‑generation sulfonylureas as effective glucose‑lowering agents while flagging a higher hypoglycaemia signal compared with newer classes.

Meta‑analyses and observational cohorts in European primary‑care databases report meaningful HbA1c reductions when glyburide is added to metformin, though precise numeric results are not specified in the supplied dataset.

Pharmacovigilance signal detection from MHRA and EU systems reinforces hypoglycaemia as the most frequently reported adverse event, including occasional severe episodes in frail or elderly patients.

Cardiovascular outcome data are mixed in older trials and lack consistent contemporary superiority; guideline panels now increasingly favour GLP‑1 receptor agonists and SGLT2 inhibitors for patients at high cardiorenal risk.

UK/EU regulatory outputs and MHRA advisories stress careful patient selection, conservative dose titration and reporting of serious events via Yellow Card.

Data Highlights: INN glyburide/glibenclamide, ATC A10BB09, with MHRA safety warnings emphasising hypoglycaemia reporting and careful use in the elderly.

Clinical Effectiveness In The Uk

Are clinicians still finding glyburide useful in everyday NHS practice?

In many NHS settings glyburide is recognised for reliable HbA1c lowering as monotherapy or as an add‑on to metformin, especially when first‑line options are not tolerated.

Real‑world NHS audits and practice reports show pragmatic use influenced by cost, local formulary choices and clinician familiarity.

Preference in many practices has shifted towards agents with lower hypoglycaemia risk or established cardiorenal benefits, but glyburide remains a practical option where appropriate.

Patient feedback collected on UK forums and primary‑care surveys highlights good daytime glucose control but frequent worry about nocturnal hypoglycaemia and appetite‑related weight gain.

For prescribers the trade‑off is predictable stimulation of insulin secretion against the need for closer monitoring and conservative dosing in higher‑risk people.

• Measured Outcomes: HbA1c change (meaningful reduction), hypoglycaemia frequency (increased), adherence issues (weight gain, meal timing).

Indications And Expanded Uses (Mhra And NhS Context)

Which patients are glyburide licensed for, and when is it discouraged?

MHRA‑aligned indications follow classical type 2 diabetes management: oral therapy to stimulate insulin secretion in patients with residual β‑cell function.

Standard indication recorded in the dataset is Type 2 diabetes; absolute contraindications include Type 1 diabetes and diabetic ketoacidosis.

Off‑label or limited uses in some UK clinics have included combinations with metformin or short‑term bridging when initiating insulin, though NHS medicines optimisation teams generally discourage use in high‑risk contexts such as pregnancy or significant renal or liver impairment.

Specialist endocrinology units may rarely use glibenclamide in selected monogenic neonatal diabetes under strict protocols, but this is a specialist pathway rather than routine MHRA licensing for neonates in the supplied dataset.

• Licensed: Type 2 diabetes (oral insulin secretagogue).
• Off‑Label / Limited Use: Short‑term bridging, specialist monogenic neonatal cases (specialist protocol required).

Composition And Brand Landscape (Uk/Eu Focus)

Which names will you see on packs, and what strengths are available?

The active ingredient is glyburide, often labelled as glibenclamide in international markets, which is the INN in the dataset.

The ATC code A10BB09 classifies it among second‑generation sulfonylureas.

Forms sold globally are oral tablets in 1.25 mg, 2.5 mg and 5 mg strengths and no topical or parenteral forms are marketed.

In the UK and EU markets the active substance typically appears under the INN glibenclamide and is supplied by generic manufacturers such as Sandoz and other regional suppliers in the dataset.

US brands like Micronase, Diabeta and Glynase Pres‑Tab are historically noted but are largely replaced by generics outside the US.

• INN vs Brand: INN = glyburide/glibenclamide; brand names vary by market and are often generic in the UK/EU.

Contraindications And Special Precautions

Who must not take glyburide and what extra caution is required?

Absolute contraindications in the dataset include Type 1 diabetes, diabetic ketoacidosis, known hypersensitivity to sulfonylureas, and significant renal or hepatic impairment.

Pregnancy and breastfeeding are listed as contraindications because glyburide crosses the placenta and milk with potential neonatal risk.

Relative precautions include G6PD deficiency, adrenal or pituitary insufficiency, malnutrition and elderly frailty, all of which increase the risk of hypoglycaemia.

Practical UK precautions are to start at the lowest dose in older adults (for example 1.25 mg), review renal function regularly and advise secure storage to keep medication out of reach of children.

Driving advice is essential; patients must avoid driving if they experience hypoglycaemia and follow DVLA guidance and local NHS advice.

• Absolute Contraindications: Type 1 diabetes; DKA; known sulfonylurea allergy; significant renal or hepatic impairment; pregnancy and breastfeeding.

Data Highlight: Follow DVLA and NHSE guidance on driving and hypoglycaemia reporting.

Dosage Guidelines (NhS‑Focused Titration & Special Populations)

How should dosing be started and adjusted in NHS practice?

Standard initiation in the dataset is low dosing of 2.5–5 mg once daily for many adults, with maintenance ranges from 1.25 mg up to 20 mg per day given as single or divided doses.

NHS practice favours starting at a low dose and titrating by small increments while monitoring capillary glucose and HbA1c.

Elderly patients should start at the lowest possible step, for example 1.25 mg, and titrate very cautiously while observing for hypoglycaemia.

Renal impairment is a key determinant: significant impairment is considered a contraindication in the supplied dataset and alternatives or cessation are recommended.

For a missed dose the advice is to take as soon as remembered unless it is close to the next scheduled dose and not to double up.

Overdose carries a risk of severe hypoglycaemia and requires urgent medical care; intravenous glucose/dextrose may be needed.

• Stepwise Titration: Start low (1.25–2.5 mg), review glucose at regular intervals, increase in small steps to effect, avoid large jumps in dose.

Interactions Overview (Food, Drugs, Mhra Yellow Card Signals)

Which medicines and foods can change how glyburide works?

Glyburide’s effect can be potentiated or reduced by many agents, and hypoglycaemia is the principal adverse effect to watch for according to the dataset.

Alcohol potentiates hypoglycaemia and should be avoided or limited while taking glyburide.

Certain antibiotics, azole antifungals and CYP2C9 inhibitors may increase the risk of hypoglycaemia by reducing clearance, while inducers such as rifampicin or herbal St John’s wort can reduce levels.

Concomitant use with other insulin secretagogues or with insulin increases hypoglycaemia risk and should generally be avoided.

MHRA Yellow Card reports commonly cite hypoglycaemia, allergic skin reactions and occasional hepatic events, and clinicians and patients are encouraged to report serious or unexpected reactions.

• Food/Beverage Cautions: Avoid heavy alcohol intake and avoid irregular meals which increase hypoglycaemia risk.

Cultural Perceptions And Patient Habits In The Uk

What do people in the UK say about taking glyburide and who do they turn to for advice?

UK patients often balance cost, convenience and perceived safety when discussing diabetes medicines on forums such as Patient.info and Mumsnet.

Common themes are concern about hypoglycaemia, trust in pharmacist counselling and requests for simpler treatment regimens.

Community pharmacists working in Boots, LloydsPharmacy and Superdrug are frequent first points of contact and often handle repeat prescriptions via the NHS Electronic Prescription Service.

Many people prefer face‑to‑face advice for dose changes, though the NHS App and e‑prescriptions have increased remote management and record keeping.

Stigma around diabetes, worries about weight gain and appetite changes influence adherence for some patients.

• Patient Concerns: Night hypos, weight gain, desire for simple regimens, need for pharmacist reassurance.

Availability And Pricing Patterns (England, Scotland, Wales, Ni)

How easy is it to get glyburide in each part of the UK and what will it cost you?

Glyburide/glibenclamide is prescription‑only across the UK and supplied through community pharmacies, NHS trust pharmacies and regulated online pharmacies according to the dataset.

In England prescription charges apply for many patients, whereas Scotland, Wales and Northern Ireland generally offer free NHS prescriptions, which affects out‑of‑pocket choices between generics and brands.

The Electronic Prescription Service streamlines repeat supplies and several MHRA‑registered online pharmacies offer fulfilment services.

Patients should always check MHRA licences and refer to the British National Formulary when in doubt.

In our online pharmacy, daonil is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Data Highlight: Typical pack strengths are 1.25 mg, 2.5 mg and 5 mg tablets; prices vary by pharmacy and by whether a prescription fee applies.

Comparable Medicines And Prescribing Preferences (NhS Formulary View)

What other medicines do clinicians consider instead of glyburide?

Alternatives commonly used in NHS practice include gliclazide (Diamicron) and glipizide among sulfonylureas, metformin as first line, repaglinide for post‑prandial control and newer classes such as DPP‑4 inhibitors, GLP‑1 receptor agonists and SGLT2 inhibitors for lower hypoglycaemia risk and cardiorenal benefits.

Choice depends on comorbidities, vulnerability to hypoglycaemia, cost and local formulary guidance.

Within the sulfonylurea class, gliclazide is often preferred for a lower hypoglycaemia profile compared with glyburide according to comparative practice patterns noted in the dataset.

• Prescribing Considerations: Metformin remains first‑line; choose GLP‑1/SGLT2 when cardiorenal benefit is needed; consider repaglinide for variable eating patterns.

Frequently Asked Questions — Common NhS Patient Questions

What are people on the NHS most often asking about glyburide?

• Q: Is glyburide safe for older adults?
• A: Use cautiously; start very low (for example 1.25 mg) and monitor glucose regularly due to increased hypoglycaemia sensitivity in older people.
• Q: Can I drink alcohol while taking it?
• A: Alcohol increases hypoglycaemia risk; limit intake and avoid heavy drinking.
• Q: What if I miss a dose?
• A: Take as soon as remembered unless it is close to the next dose; do not double up.
• Q: Is it available on the NHS?
• A: Yes, as a prescription medicine, but availability depends on local formulary and clinician preference; England prescription charges may apply while Scotland, Wales and Northern Ireland typically have free prescriptions.

Guidelines For Proper Use (Pharmacist Counselling And NhS Support)

What should your pharmacist tell you when dispensing glyburide?

Counselling should cover the mechanism of action — glyburide stimulates insulin secretion by closing β‑cell potassium channels — the dosing schedule, recognition and treatment of hypoglycaemia, safe storage and the importance of Yellow Card reporting for adverse events.

Pharmacists should check renal and hepatic status, review alcohol use and driving risk, and confirm concordance with regular meals when advising patients.

Advise on storage: keep at 20–25°C, protect from moisture and store in original packaging away from heat.

Refer patients to NHS resources such as the NHS App, NHS 111 and local Diabetes Education or GTT clinics for structured support.

• Counselling Checklist: Confirm indication, discuss dose and titration, explain hypoglycaemia signs, review interactions and advise on secure storage.

Emergency Steps For Hypoglycaemia:

1. Give quick‑acting carbohydrate (glucose gel or sugary drink) immediately for conscious patients.
2. Recheck blood glucose after 10–15 minutes and repeat carbohydrate if still low.
3. If unconscious, call emergency services and seek intravenous glucose or glucagon administration.

Delivery Across United Kingdom